CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas
- 15 November 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 88 (4) , 554-557
- https://doi.org/10.1002/1097-0215(20001115)88:4<554::aid-ijc6>3.0.co;2-q
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic HybridizationThe American Journal of Pathology, 1999
- CDKN2/p16 Predicts Survival in Oligodendrogliomas: Comparison with AstrocytomasJournal of Neuro-Oncology, 1999
- Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic OligodendrogliomasJNCI Journal of the National Cancer Institute, 1998
- Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in GlioblastomasJournal of Neuropathology and Experimental Neurology, 1998
- The Prognostic Significance of Ki-67 Labeling Indices for OligodendrogliomasNeurosurgery, 1997
- A Molecular Genetic Model of Astrocytoma HistopathologyBrain Pathology, 1997
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proceedings of the National Academy of Sciences, 1996
- Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomasCancer, 1996
- 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancersNature Medicine, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958